HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS)

Posted by Brian Himes on May 4th, 2026

Krystal Biotech (NASDAQ:KRYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $310.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 11.75% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group increased their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Citigroup raised their price target on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Guggenheim raised their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Bank of America raised their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average target price of $326.25.

Check Out Our Latest Analysis on Krystal Biotech

Krystal Biotech Stock Performance

KRYS traded up $11.37 on Monday, reaching $277.41. 319,788 shares of the company’s stock were exchanged, compared to its average volume of 287,952. The company’s 50 day moving average is $261.72 and its 200-day moving average is $246.50. The company has a market cap of $8.17 billion, a price-to-earnings ratio of 40.48 and a beta of 0.50. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $298.30.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. Sell-side analysts forecast that Krystal Biotech will post 7.58 EPS for the current year.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dino A. Rossi sold 18,950 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $261.41, for a total value of $4,953,719.50. Following the transaction, the director owned 78,691 shares in the company, valued at $20,570,614.31. This trade represents a 19.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 129,164 shares of company stock valued at $34,538,578. Company insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of Krystal Biotech by 145.2% during the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after acquiring an additional 964 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after acquiring an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after acquiring an additional 688 shares during the period. Empowered Funds LLC acquired a new position in shares of Krystal Biotech during the first quarter valued at $218,000. Finally, Cetera Investment Advisers boosted its holdings in shares of Krystal Biotech by 107.9% during the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after acquiring an additional 2,255 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.